SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Venture Global, Inc. engages in the provision of United States liquefied natural gas sourced from resource rich North American natural gas basins. It operates through the following segments: Calcasieu Project, Plaquemines Project, CP2 Project, and Sales and shipping. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is gaining momentum as supply disruptions in the Strait of Hormuz and extended force majeure from competitors tighten the global LNG market, driving up spot prices. The community is actively discussing the potential for a blowout earnings report and raised forward guidance, viewing the stock as a strategic infrastructure asset that remains well-positioned to capitalize on elevated energy spreads despite ongoing geopolitical volatility.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is currently under the microscope as market participants debate the impact of delayed regulatory legislation and ongoing institutional capital rotation. The community remains divided, with active discussions focused on whether recent price stagnation represents an attractive accumulation zone or a structural weakening driven by broader market uncertainty.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum Holdings is trending as investors monitor supply bottlenecks for indium phosphide (InP) lasers and optical components amid surging demand for AI infrastructure. The community is actively debating the sector's valuation and volatility ahead of upcoming earnings, while weighing the impact of potential trade restrictions on critical data center components.

Microstrategy Incorporated. The Group's principal activity is to provide business intelligence software that enable companies to analyze raw data stored across their enterprise. The solutions offered by the Group include MicroStrategy 7i, MicroStrategy Intelligence Server, MicroStrategy Web, MicroStrategy Narrowcast Server, MicroStrategy MDX Adapter and MicroStrategy Agent. The Group also offers product support and other services such as technical account management, consulting, education and technical support. These solutions and services are marketed worldwide to the retail, telecommunications, financial services, pharmaceuticals, manufacturing and technology industries. The customers include Bank of Montreal, Ace Hardware Corporation, AT&T, Grange Insurance, AmerisourceBergen Corporation, E.I. Dupont de Nemours and Company, TRX Data Services and US Postal Service.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is experiencing heightened volatility and active community debate as investors react to ongoing stock dilution, the company's aggressive Bitcoin treasury strategy, and failed legislative attempts to pass crypto-focused regulatory bills. While bulls remain focused on potential long-term upside tied to Bitcoin's price movements, a vocal segment of the community continues to raise concerns regarding the impact of continuous share issuance and the company's long-term sustainability.

Coherent Corp. engages in the development, refinement, manufacturing, and marketing of engineered materials, opto-electronic components and devices, and lasers for use in the industrial, communications, electronics, and instrumentation markets. It operates through the following segments: Networking, Materials, and Lasers. The Networking segment leverages compound semiconductor technology platforms and deep knowledge of end-user applications. The Materials segment markets engineered materials and optoelectronic devices. The Lasers segment serves industrial customers in semiconductor capital equipment, display capital equipment, precision manufacturing, and aerospace and defense, as well as instrumentation customers in life sciences and scientific research. The company was founded by Carl J. Johnson in 1971 and is headquartered in Saxonburg, PA.

Coherent Corp

Coherent Corp is trending as investors monitor it alongside other photonics leaders in the AI infrastructure stack, focusing on its critical role in high-speed optical networking and indium phosphide capacity expansion. Community discussion centers on the company's strategic positioning within the AI ecosystem as a beneficiary of hyperscaler connectivity demand and supply chain constraints.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is facing intense scrutiny as market participants debate the impact of the proposed CLARITY Act and broader economic uncertainty. While some traders are focused on crucial support levels and potential institutional accumulation via ETF inflows, others are expressing bearish sentiment due to geopolitical tensions and concerns over the long-term cycle.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending as investors aggressively position for the highly anticipated IZAR-1 Phase 3 trial data, with community discussion centered on potential best-in-class efficacy and imminent acquisition speculation. While the stock has seen significant short interest and volatility, the core investor base remains focused on upcoming catalysts, including BLA submissions and data readouts that could serve as major valuation inflections.

Applied Materials, Inc. engages in provision of materials engineering solutions used to produce semiconductors. The firm also focuses on design, development, production, and servicing of the critical wafer fabrication tools used for customers to manufacture semiconductors. It operates through the following segments: Semiconductor Systems and Applied Global Services (AGS). The Semiconductor Systems segment includes designing, development, manufacturing and sale of equipment used to fabricate semiconductor chips referred to as integrated circuits. The AGS segment engages in provision of services, spares, and factory automation software to customer fabrication plants globally. The company was founded on November 10, 1967 and is headquartered in Santa Clara, CA.

Applied Materials Inc.

Applied Materials is currently trending as a prominent participant in the AI infrastructure and semiconductor equipment supercycle, with community discussion centered on its role as a key supplier for advanced chip fabrication and memory capacity. Investors are closely monitoring its high valuation and insider activity alongside broader analyst optimism, while many community members express concerns about the sustainability of the stock's parabolic momentum during a volatile earnings and macroeconomic season.

Cash Cat

Cash Cat is trending as market participants debate its potential as a prominent memecoin on the Robinhood chain, drawing comparisons to other high-profile speculative assets. The community remains sharply divided, with some investors actively accumulating the token based on its perceived launchpad status while others voice skepticism regarding its long-term viability and volatility.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is facing intense scrutiny as shareholders debate the company's commercial execution following the expiration of the TDAPA reimbursement period, with community discussion centered on aggressive institutional accumulation versus concerns over leadership communication and potential share price manipulation. Investors remain focused on the company's ability to secure large-scale contracts and the clinical validation of its diversified anti-infective portfolio, while pending legislative efforts like K-CAPA and upcoming quarterly earnings serve as critical focal points for the stock's future trajectory.

statis crypto Watchlist

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NTLA Q2 Earnings In Line, Top Line Misses on Lower Regeneron Revenues

Intellia's Q2 loss matches estimates, but revenues fall 46.2% as lower Regeneron collaboration revenues weigh on results.

Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Lags Revenue Estimates

Intellia Therapeutics (NTLA) delivered earnings and revenue surprises of 0.00% and -47.22%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Protagonist Therapeutics (PTGX) Beats Q2 Earnings Estimates

Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of +8.53% and -3.12%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

3 Promising Genomics Stocks to Add to Your Portfolio in 2026

Genomics is reshaping healthcare, and these three stocks - MYGN, SANA and WVE - stand out as rapid advances in personalized medicine and synthetic biology continue to transform the industry.

This Etsy Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday

Wall Street analysts change ratings for Pentair, Intellia Therapeutics, Etsy, Nutrien, and Ionis Pharmaceuticals. See what other analysts say.read more...

NTLA Surges 38% in a Month: Should You Buy, Sell or Hold the Stock?

Intellia gains 38% in a month as additional positive phase III lonvo-z data and other pipeline progress boost investor optimism.

Strength Seen in Mirum Pharmaceuticals (MIRM): Can Its 5.5% Jump Turn into More Strength?

Mirum Pharmaceuticals (MIRM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?

Key PointsIntellia Therapeutics is leveraging its strategic partnership with Regeneron to advance a deep pipeline of CRISPR-based gene editing therapies...

This Stock Is Up 58% This Year. Is It too Late to Buy?

Key PointsOne of Intellia Therapeutics' leading candidates recently aced a phase 3 study...

NTLA Posts Strong Additional Phase III Data From HAE Study, Stock Up

Intellia jumps after additional phase III HAELO data showed lonvo-z cut on-demand-treated attacks by 89% and moderate-to-severe episodes by 91%.

Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Nasdaq, S&P 500 Futures Cheer Iran Breakthrough, Crude Slides: Why SPCX, NVDA, RKLB, ASTS, RCAT, NTLA Are Keeping Traders Hooked

Equity

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

NTLAIntellia Therapeutics Inc

Fundamentals

Connect Stocktwits to ChatGPT

Latest NTLA News